Medical - Devices
Compare Stocks
4 / 10Stock Comparison
TIVC vs GKOS vs NVCR vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
TIVC vs GKOS vs NVCR vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $3M | $7.85B | $1.92B | $16.97B |
| Revenue (TTM) | $482K | $551M | $674M | $4.13B |
| Net Income (TTM) | $-8M | $-189M | $-173M | $544M |
| Gross Margin | -58.1% | 78.1% | 75.2% | 52.8% |
| Operating Margin | -15.5% | -15.6% | -27.2% | 17.5% |
| Forward P/E | — | — | — | 17.2x |
| Total Debt | $0.00 | $140M | $290M | $2.63B |
| Cash & Equiv. | $2M | $91M | $103M | $1.96B |
TIVC vs GKOS vs NVCR vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Tivic Health System… (TIVC) | 100 | 0.0 | -100.0% |
| Glaukos Corporation (GKOS) | 100 | 333.9 | +233.9% |
| NovoCure Limited (NVCR) | 100 | 16.2 | -83.8% |
| Hologic, Inc. (HOLX) | 100 | 101.2 | +1.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TIVC vs GKOS vs NVCR vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TIVC plays a supporting role in this comparison — it may shine differently against other peers.
GKOS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 32.3%, EPS growth -18.4%, 3Y rev CAGR 21.5%
- 457.1% 10Y total return vs HOLX's 124.3%
- Lower volatility, beta 1.20, Low D/E 21.3%, current ratio 4.69x
- 32.3% revenue growth vs TIVC's -33.7%
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
HOLX carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- beta 0.41
- Beta 0.41, current ratio 3.75x
- 13.2% margin vs TIVC's -15.6%
- Beta 0.41 vs NVCR's 2.20, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.3% revenue growth vs TIVC's -33.7% | |
| Quality / Margins | 13.2% margin vs TIVC's -15.6% | |
| Stability / Safety | Beta 0.41 vs NVCR's 2.20, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +52.0% vs TIVC's -76.0% | |
| Efficiency (ROA) | 6.1% ROA vs TIVC's -173.3%, ROIC 9.4% vs -7.8% |
TIVC vs GKOS vs NVCR vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
TIVC vs GKOS vs NVCR vs HOLX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HOLX leads in 3 of 6 categories
GKOS leads 1 • TIVC leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HOLX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX is the larger business by revenue, generating $4.1B annually — 8561.0x TIVC's $482,000. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to TIVC's -15.6%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $482,000 | $551M | $674M | $4.1B |
| EBITDAEarnings before interest/tax | -$7M | -$40M | -$165M | $974M |
| Net IncomeAfter-tax profit | -$8M | -$189M | -$173M | $544M |
| Free Cash FlowCash after capex | -$6M | -$18M | -$48M | $1000M |
| Gross MarginGross profit ÷ Revenue | -58.1% | +78.1% | +75.2% | +52.8% |
| Operating MarginEBIT ÷ Revenue | -15.5% | -15.6% | -27.2% | +17.5% |
| Net MarginNet income ÷ Revenue | -15.6% | -34.3% | -25.7% | +13.2% |
| FCF MarginFCF ÷ Revenue | -12.7% | -3.4% | -7.1% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.9% | +41.2% | +12.3% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +49.9% | -6.3% | -100.0% | -9.2% |
Valuation Metrics
Evenly matched — GKOS and NVCR and HOLX each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3M | $7.9B | $1.9B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $599,551 | $7.9B | $2.1B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -40.90x | -13.80x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 3.34x | 15.47x | 2.92x | 4.14x |
| Price / BookPrice ÷ Book value/share | 116.77x | 11.69x | 5.51x | 3.43x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 18.44x |
Profitability & Efficiency
HOLX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-2 for TIVC. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs GKOS's 3/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.0% | -26.5% | -50.8% | +11.0% |
| ROA (TTM)Return on assets | -173.3% | -20.1% | -16.5% | +6.1% |
| ROICReturn on invested capital | -7.8% | -9.2% | -16.4% | +9.4% |
| ROCEReturn on capital employed | -180.0% | -10.3% | -28.9% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 5 | 7 |
| Debt / EquityFinancial leverage | — | 0.21x | 0.85x | 0.52x |
| Net DebtTotal debt minus cash | -$2M | $49M | $187M | $667M |
| Cash & Equiv.Liquid assets | $2M | $91M | $103M | $2.0B |
| Total DebtShort + long-term debt | $0 | $140M | $290M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | — | -18.69x | -96.80x | 8.00x |
Total Returns (Dividends Reinvested)
GKOS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $1 for TIVC. Over the past 12 months, GKOS leads with a +52.0% total return vs TIVC's -76.0%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs TIVC's -83.3% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -27.5% | +21.2% | +28.3% | +1.9% |
| 1-Year ReturnPast 12 months | -76.0% | +52.0% | +1.1% | +37.1% |
| 3-Year ReturnCumulative with dividends | -99.5% | +128.7% | -75.7% | -8.5% |
| 5-Year ReturnCumulative with dividends | -100.0% | +61.5% | -91.3% | +15.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | +457.1% | +30.3% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -83.3% | +31.7% | -37.6% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs TIVC's 18.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.19x | 1.20x | 2.20x | 0.41x |
| 52-Week HighHighest price in past year | $5.60 | $146.75 | $20.06 | $76.04 |
| 52-Week LowLowest price in past year | $0.74 | $73.16 | $9.82 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +18.4% | +91.4% | +83.9% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 47.6 | 63.0 | 69.8 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 344K | 678K | 1.5M | 10.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GKOS as "Buy", NVCR as "Buy", HOLX as "Hold". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 3.9% for HOLX (target: $79).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $146.67 | $33.50 | $79.00 |
| # AnalystsCovering analysts | — | 24 | 15 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.4% |
HOLX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GKOS leads in 1 (Total Returns). 1 tied.
TIVC vs GKOS vs NVCR vs HOLX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is TIVC or GKOS or NVCR or HOLX a better buy right now?
For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.
3% revenue growth year-over-year, versus -33. 7% for Tivic Health Systems, Inc. (TIVC). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TIVC or GKOS or NVCR or HOLX?
Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.
5%, compared to -100. 0% for Tivic Health Systems, Inc. (TIVC). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus TIVC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TIVC or GKOS or NVCR or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — TIVC or GKOS or NVCR or HOLX?
By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.
3% versus -33. 7% for Tivic Health Systems, Inc. (TIVC). On earnings-per-share growth, the picture is similar: Tivic Health Systems, Inc. grew EPS 88. 9% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TIVC or GKOS or NVCR or HOLX?
Hologic, Inc.
(HOLX) is the more profitable company, earning 13. 8% net margin versus -725. 0% for Tivic Health Systems, Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -725. 8% for TIVC. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TIVC or GKOS or NVCR or HOLX more undervalued right now?
Analyst consensus price targets imply the most upside for NVCR: 99.
0% to $33. 50.
07Which pays a better dividend — TIVC or GKOS or NVCR or HOLX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is TIVC or GKOS or NVCR or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Tivic Health Systems, Inc. (TIVC) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, TIVC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TIVC and GKOS and NVCR and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TIVC is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.